DOCSLIB.ORG

Kopecky Et Al.: Restoration of Renal Function Does Not Correct Impairment of Uremic HDL Properties

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kopecky Et Al.: Restoration of Renal Function Does Not Correct Impairment of Uremic HDL Properties Kopecky et al.: Restoration of Renal Function does not correct Impairment of Uremic HDL Properties Supplemental Figure 1. Quantification of MS-identified proteins between the patient groups. Relative abundance of HDL proteins calculated by a peptide index (PI) from (A) KTxgood versus KTxpoor patients, (B) KTxgood versus ESRD patients and (C) KTxpoor versus ESRD patients. Proteins with PI values below ±0.01 are not shown. Data are from 14 subjects in each group. *p<0.05. Supplemental Figure 2 Impaired functional properties of transplant HDL are not dependent on graft function. Values in red represent an alternative classification of kidney recipients with good graft function defined by GFR >50ml/min/1.73m2. (A) Antioxidative properties of HDL were measured by its arylesterase activity. (B) Cholesterol efflux capacity of HDL was assessed by measuring its ability to efflux [3H]- cholesterol from THP-1 macrophages. (C) Cholesterol content in leukocytes of study subjects. (D) Correlation analysis of cholesterol content in leukocytes and cholesterol efflux capability of HDL. Pearson’s correlation coefficient is noted for the plot. *p<0.05, **p<0.01, ***p<0.001. Supplemental Figure 3 Atheroprotective HDL properties do not improve with recovery of renal function. HDL from patients on hemodialysis (pre HD), who were transplanted (post Tx) (n=4) or remained on hemodialysis (post HD) (n=8) was subjected to functional analysis. (A) Arylesterase activity was measured to compare antioxidative capacity between the two groups. (B) HDL was examined for its ability to efflux [3H]-cholesterol from THP-1 macrophages. Supplemental Figure 4 Immunoblot of HDL-associated proteins in patients remaining on hemodialysis and after kidney transplantation. HDL samples (10µg/lane) from (A) hemodialysis patients (pre HD), who were transplanted (post Tx) or (B) remained on HD (post HD) were subjected to immunoblot analysis and probed with the indicated antibodies. Supplemental Figure 5 Impaired atheroprotective properties of transplant HDL are not influenced by the type of CNI. Values in blue in the transplant groups represent patients receiving tacrolimus. (A,B) HDL from study subjects was examined for their ability to efflux [3H]-cholesterol from THP-1 macrophages. (C,D) Arylesterase activity of HDL-associated paraoxonase was measured using phenylacetate as substrate. (E,F) Free cholesterol content was measured in leukocytes of study subjects. The amount of cholesterol is expressed normalized to total protein amount of each sample. *p<0.05, **p<0.01, ***p<0.001. CNI, calcineurin inhibitor; Cs, cyclosporine. Tac, tacrolimus. Supplemental Table 1. Proteins detected by MS analysis in HDL from KTxgood, KTxpoor, ESRD patients and healthy controls healthy controls (n=15) KTxgood (n=14) KTxpoor (n=14) ESRD (n=14) Proteins % of total identified % of total identified % of total identified % of total identified PSM peptides in PSM peptides in PSM peptides in PSM peptides in Lipid metabolism Apolipoprotein A-I 288.7 40.38 15 567.1 50.26 14 480.1 38.15 14 810.9 53.00 14 Apolipoprotein A-II 126.9 19.03 15 187.3 16.99 14 160.9 12.72 14 227.1 14.67 14 Apolipoprotein E 25.6 3.42 15 29.8 1.90 12 31.4 2.55 14 40.9 2.68 14 Apolipoprotein A-IV 22.7 2.91 15 37.9 2.37 12 45.0 3.55 14 40.5 2.61 14 Apolipoprotein C-III 18.1 2.45 15 24.8 1.45 11 24.1 1.98 14 37.1 2.44 14 Apolipoprotein C-II 7.8 1.19 15 7.8 0.57 13 8.2 0.67 14 9.8 0.64 14 Apolipoprotein M 9.9 1.18 14 11.0 0.78 13 12.4 1.03 14 11.3 0.71 14 Serum paraoxonase/arylesterase 1 13.9 1.80 14 15.2 0.99 12 11.3 0.92 14 13.3 0.86 14 Apolipoprotein B-100 14.9 1.76 14 35.6 2.10 12 87.5 5.53 13 26.5 1.69 14 Apolipoprotein C-I 10.4 1.25 14 10.4 0.66 12 11.7 0.97 14 15.2 1.00 14 Apolipoprotein D 14.6 1.74 14 19.4 1.33 13 19.6 1.61 14 19.6 1.28 14 Apolipoprotein F 4.1 0.52 14 5.0 0.29 11 4.1 0.33 14 3.4 0.22 14 Apolipoprotein L1 4.5 0.45 12 8.1 0.52 12 7.3 0.58 14 4.6 0.30 14 Apolipoprotein C-IV 2.2 0.20 11 2.8 0.12 8 3.6 0.20 10 3.8 0.26 14 Serum paraoxonase/lactonase 3 2.9 0.21 9 2.0 0.08 8 1.6 0.10 10 2.3 0.14 13 Apolipoprotein(a) 8.7 0.42 6 5.5 0.28 11 15.4 0.93 12 9.5 0.56 13 Phosphatidylcholine-sterol acyltransferase 1.8 0.09 6 1.5 0.05 6 1.8 0.06 6 - - 0 Phospholipid transfer protein 1.0 0.01 1 1.3 0.02 3 1.3 0.02 3 1.5 0.01 2 Cholesteryl ester transfer protein 1.0 0.01 1 1.0 0.01 2 1.5 0.02 2 - - 0 Pulmonary surfactant-associated protein B - - 0 3.0 0.01 1 1.0 0.01 1 2.0 0.03 3 Acute phase response Serum amyloid A-4 protein 9.0 1.08 14 11.8 0.67 11 10.2 0.87 14 11.1 0.73 14 Serum amyloid A protein 4.8 0.53 13 9.4 0.53 11 11.5 0.94 14 11.9 0.77 14 Alpha-2-HS-glycoprotein 3.0 0.31 12 8.7 0.57 13 12.1 0.76 12 5.1 0.25 11 Alpha-1-acid glycoprotein 1 3.5 0.31 10 7.7 0.38 10 9.1 0.59 12 5.9 0.35 13 Serum amyloid A-2 protein 1.3 0.08 3 5.2 0.13 5 6.7 0.24 6 8.0 0.26 7 Alpha-1-acid glycoprotein 2 - - 0 3.5 0.03 2 4.3 0.08 4 5.0 0.02 1 Complement Beta-2-glycoprotein 1 7.5 0.11 2 8.4 0.28 7 9.5 0.54 11 4.1 0.19 10 Ig gamma-1 chain C region 7.4 0.70 12 9.8 0.48 10 12.0 0.93 14 11.3 0.61 12 Ig kappa chain C region 2.8 0.24 11 4.4 0.23 11 5.6 0.42 13 6.3 0.31 11 Complement C3 2.7 0.15 7 2.7 0.08 6 4.2 0.20 9 1.0 0.03 6 Ig gamma-3 chain C region 2.0 0.03 2 4.7 0.13 6 3.2 0.22 12 4.4 0.18 9 Ig gamma-2 chain C region 2.0 0.01 1 4.0 0.02 1 3.0 0.02 1 3.5 0.03 2 Ig lambda-2 chain C regions 1.8 0.17 12 4.0 0.15 8 2.9 0.21 13 4.5 0.22 11 Complement C4-A 1.0 0.01 1 1.0 0.01 1 2.0 0.02 2 1.0 0.01 3 Complement factor D - - 0 - - 0 2.7 0.13 9 3.3 0.14 9 Ig kappa chain V-III region SIE - - 0 1.5 0.01 2 2.0 0.02 2 2.0 0.03 3 Protea se inhibitors Alpha-1-antitrypsin 9.6 1.12 14 23.6 1.27 11 32.2 2.42 14 10.9 0.64 13 Haptoglobin 3.1 0.24 9 6.3 0.28 9 7.0 0.34 9 7.3 0.26 8 Alpha-1-antichymotrypsin 2.0 0.05 3 4.4 0.14 7 4.1 0.19 9 4.0 0.02 1 Plasma protease C1 inhibitor 2.0 0.01 1 3.0 0.04 3 2.1 0.07 7 1.8 0.03 4 Kininogen-1 1.0 0.02 2 1.3 0.02 3 2.4 0.06 5 - - 0 Protein AMBP - - 0 8.1 0.26 7 12.9 0.99 14 12.4 0.80 14 Pigment epithelium-derived factor - - 0 2.5 0.02 2 3.1 0.14 9 1.3 0.04 6 Cystatin-C - - 0 - - 0 1.3 0.04 6 1.5 0.03 4 Immune response Platelet basic protein 4.6 0.51 13 6.3 0.35 11 6.1 0.48 14 6.6 0.33 11 Platelet factor 4 2.8 0.11 5 2.6 0.09 7 4.3 0.21 9 3.0 0.08 6 Ig alpha-1 chain C region 2.6 0.15 7 7.4 0.18 5 3.2 0.09 6 5.0 0.13 6 HLA class I histocompatibility antigen, B-58 alpha chain 2.5 0.04 2 2.0 0.01 1 1.0 0.01 2 - 0.00 0 Alpha-1B-glycoprotein 2.2 0.09 5 2.8 0.08 6 3.4 0.19 11 1.4 0.03 5 Zinc-alpha-2-glycoprotein 1.0 0.01 1 2.8 0.05 4 5.3 0.18 7 2.2 0.05 5 Beta-2-microglobulin - - 0 1.3 0.02 4 3.6 0.23 12 5.7 0.37 14 Cathelicidin antimicrobial peptide - - 0 1.0 0.01 2 1.2 0.04 6 1.0 0.02 4 Transp ort Serum albumin 94.6 11.95 15 141.0 10.10 14 148.6 11.52 14 122.2 7.85 14 Serotransferrin 8.2 0.77 12 12.6 0.71 11 10.1 0.71 13 8.0 0.32 9 Vitamin D-binding protein 3.4 0.24 9 9.4 0.37 8 12.0 0.72 11 4.7 0.23 11 Transthyretin 1.9 0.16 10 2.6 0.14 10 4.2 0.30 13 2.8 0.15 12 Hemopexin 1.8 0.17 12 4.2 0.18 9 4.2 0.29 13 3.0 0.13 10 Retinol-binding protein 4 1.0 0.02 2 2.0 0.06 7 5.8 0.37 12 4.4 0.28 14 Hemoglobin subunit beta 1.0 0.01 1 2.7 0.04 3 3.0 0.02 1 2.5 0.05 4 Kinesin-like protein KIFC3 1.0 0.01 1 1.3 0.02 3 1.0 0.02 4 1.0 0.01 1 Flotillin-1 1.0 0.01 2 1.0 0.01 3 1.0 0.01 1 1.0 0.01 2 Other Keratin, type II cytoskeletal 1 5.4 0.45 10 3.5 0.12 6 5.4 0.30 10 4.4 0.18 8 Haptoglobin-related protein 3.3 0.10 3 7.3 0.10 3 4.3 0.10 4 8.5 0.07 2 Fibrinogen beta chain 3.0 0.02 1 2.3 0.06 6 2.4 0.09 7 2.0 0.01 1 Keratin, type I cytoskeletal 9 2.7 0.18 7 1.5 0.02 2 4.3 0.10 4 4.3 0.07 3 Thymosin beta-4 2.4 0.14 8 3.0 0.11 7 4.1 0.26 12 2.4 0.08 8 SH3 domain-binding glutamic acid-rich-like protein 3 2.0 0.02 1 1.3 0.04 6 1.5 0.06 8 1.5 0.01 2 Keratin, type I cytoskeletal 10 1.8 0.12 8 2.5 0.06 4 1.6 0.08 9 2.7 0.04 3 Angiotensinogen 1.5 0.02 2 1.8 0.04 5 3.6 0.16 9 1.8 0.03 4 Clusterin 1.5 0.09 8 1.2 0.04 6 1.1 0.06 10 1.4 0.03 5 UDP-glucose:glycoprotein glucosyltransferase 2 1.5 0.07 4 1.0 0.03 5 1.6 0.08 9 1.1 0.05 10 Profilin-1 1.2 0.06 6 1.8 0.07 8 1.9 0.10 10 - - 0 Fibrinogen alpha chain 1.0 0.01 1 3.3 0.06 4 3.8 0.23 11 2.4 0.10 9 Retinol dehydrogenase 14 1.0 0.05 5 1.0 0.01 2 1.0 0.02 3 1.0 0.01 2 Zinc finger protein 134 1.0 0.07 9 1.1 0.06 9 1.1 0.07 11 1.1 0.04 7 Prenylcysteine oxidase 1 1.0 0.05 5 1.0 0.005 1 1.5 0.02 2 - - 0 Neurabin-1 1.0 0.02 2 1.0 0.004 1 - - 0 1.0 0.004 1 Methyltransferase-like protein 13 1.0 0.02 2 - - 0 1.0 0.02 3 1.0 0.01 2 Fibrinogen gamma chain - - 0 2.0 0.02 2 2.3 0.04 4 1.0 0.01 2 Leucine-rich alpha-2-glycoprotein - - 0 2.0 0.03 3 1.1 0.06 9 1.0 0.004 1 Tropomyosin alpha-4 chain - - 0 1.0 0.004 1 1.5 0.03 4 1.0 0.004 1 HDL from 14 subjects per patient group and 15 healthy controls was isolated by gradient ultracentrifugation and used for shotgun proteomic analysis.
Load more

Recommended publications
  • Association of Paraoxonase-2 Genetic Variation with Serum
    ASSOCIATION OF PARAOXONASE-2 GENETIC VARIATION WITH SERUM PARAOXONASE ACTIVITY AND SYSTEMIC LUPUS ERYTHEMATOSUS by Sudeshna Dasgupta B.S., University of Calcutta, India, 2001 M.S., University of Calcutta, India, 2003 Submitted to the Graduate Faculty of Graduate School of Public Health in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2008 UNIVERSITY OF PITTSBURGH Graduate School of Public Health This dissertation was presented by Sudeshna Dasgupta It was defended on November 3rd, 2008 and approved by F. Yesim Demirci M.D., Research Assistant Professor, Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh Susan M. Manzi, MD, MPH, Associate Professor, Department of Medicine, School of Medicine and Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh Candace M. Kammerer, Ph.D. Associate Professor, Department of Human Genetics Graduate School of Public Health, University of Pittsburgh Committee Chair Person Robert E. Ferrell, Ph.D. Professor, Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh Dissertation Advisor, M. Ilyas Kamboh, Ph.D. Professor and Chair, Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh ii Dedicated to my mother Mrs. Susmita Dasgupta and my father Dr. Gautam Dasgupta iii Copyright © by Sudeshna Dasgupta 2008 iv M. Ilyas Kamboh PhD ASSOCIATION OF PARAOXONASE-2 GENETIC VARIATION WITH SERUM PARAOXONASE ACTIVITY AND SYSTEMIC LUPUS ERYTHEMATOSUS Sudeshna Dasgupta, PhD University of Pittsburgh, 2008 SLE, a severe autoimmune disease is of major public health relevance since it predominantly affects women at child bearing age and even though immunosuppressives have increased the life span of SLE patients, lack of absolute cure is still troubling.
    [Show full text]
  • Ameliorating Oxidative Stress and Inflammation by Hesperidin And
    Turk J Biochem 2019; 44(2): 207–217 Research Article Thoria Donia*, Samar Eldaly and Ehab M.M. Ali Ameliorating oxidative stress and inflammation by Hesperidin and vitamin E in doxorubicin induced cardiomyopathy Doxorubicin ile İndüklenmiş Kardiyomiyopatide Hesperidin ve E Vitamini ile Oksidatif Stres ve İnflamasyonun İyileştirilmesi https://doi.org/10.1515/tjb-2018-0156 Conclusion: HSP and VIT.E possess a protective effect Received May 7, 2018; accepted July 3, 2018; previously published against DOX-induced cardiomyopathy via inhibiting oxi- online September 5, 2018 dative stress, inflammation, and apoptosis. Abstract Keywords: Cardiomyopathy; Doxorubicin; Hesperidin; Vitamin E; Oxidative stress. Background: Doxorubicin (DOX) is a common chemother- apeutic drug. However, it causes cardiomyopathy which reduces its clinical use in human cancer therapy. Öz Objective: The purpose of our study was to assess the cardioprotective effect of hesperidin (HSP) and vitamin E Giriş: Doksorubisin (DOX) yaygın bir kemoterapötik ilaçtır. (VIT.E) against DOX-induced cardiomyopathy. Bununla birlikte, kardiyomiyopatiye neden olduğu için bu Material and methods: Seventy rats were allocated into durum ilaçın insan kanser tedavisinde klinik kullanımını seven groups: control, HSP (50 mg/kg, orally), VIT.E azaltır. (100 mg/kg orally), DOX [4 mg/kg, intraperitoneally (i.p.)], Amaç: Çalışmamızın amacı, DOX ile indüklenen kardiyo- DOX + HSP, DOX + VIT.E and DOX + HSP + VIT.E. miyopatiye karşı hesperidin (HSP) ve vitamin E’nin (VIT.E) Results: Our findings showed that serum lactate dehy- kardiyoprotektif etkisini değerlendirmektir. drogenase (LDH), creatine kinase (CK), myeloperoxidase Gereç ve Yöntemler: Yetmiş sıçan yedi gruba ayrıldı: (MPO), cardiac catalase and caspase activities as well kontrol, HSP (50 mg/kg, oral), VIT.E (100 mg/kg oral), DOX as cardiac malondialdehyde (MDA) and serum nitric [4 mg/kg, intraperitoneal (ip)], DOX + HSP, DOX + VIT.E ve oxide (NO) concentrations were reduced DOX + HSP or DOX + HSP + VIT.E.
    [Show full text]
  • Paraoxonase 2 Is Critical for Non-Small Cell Lung Carcinoma Proliferation
    University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 5-2019 Paraoxonase 2 is critical for non-small cell lung carcinoma proliferation. Aaron Whitt University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Cancer Biology Commons, Molecular Biology Commons, and the Pharmacology Commons Recommended Citation Whitt, Aaron, "Paraoxonase 2 is critical for non-small cell lung carcinoma proliferation." (2019). Electronic Theses and Dissertations. Paper 3236. https://doi.org/10.18297/etd/3236 This Master's Thesis is brought to you for free and open access by ThinkIR: The nivU ersity of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The nivU ersity of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. PARAOXONASE 2 IS CRITICAL FOR NON-SMALL CELL LUNG CARCINOMA PROLIFERATION By Aaron Whitt B.S., Morehead State University, 2010 A Thesis Submitted to the Faculty of the School of Medicine of the University of Louisville in Partial Fulfillment of the Requirements for the Degree of Master of Science in Pharmacology and Toxicology Department of Pharmacology and Toxicology University of Louisville Louisville, Kentucky May, 2019 PARAOXONASE 2 IS CRITICAL FOR NON-SMALL CELL LUNG CARCINOMA PROLIFERATION By Aaron Gregory Whitt B.S., Morehead State University, 2010 A Thesis Approved on December 13, 2018 By the following Thesis Committee _______________________________ Chi Li, Ph. D.
    [Show full text]
  • Methodological Aspects and Relevance of the Study of Vegetable Oil, Fat and Lipoprotein Oxidation Using Pancreatic Lipase and Arylesterase
    M. NUS et al.: Study of Fat with Pancreatic Lipase and Arylesterase, Food Technol. Biotechnol. 44 (1) 1–15 (2006) 1 ISSN 1330-9862 review (FTB-1467) Methodological Aspects and Relevance of the Study of Vegetable Oil, Fat and Lipoprotein Oxidation Using Pancreatic Lipase and Arylesterase Meritxell Nus2, Francisco J. Sánchez-Muniz2 and José M. Sánchez-Montero1* 1Biotransformations Group, Organic and Pharmaceutical Chemistry Department, Faculty of Pharmacy, Complutense University, E-28040 Madrid, Spain 2Nutrition and Bromatology I (Nutrition) Department, Faculty of Pharmacy, Complutense University, E-28040 Madrid, Spain Received: July 4, 2005 Revised version: November 23, 2005 Accepted: November 29, 2005 Summary Fats and oils as major dietary components are involved in the development of chronic diseases. In this paper the physiological relevance and some methodological aspects re- lated to the determination of two enzymes enrolled in metabolism of fat – pancreatic li- pase and arylesterase – are discussed. Pancreatic lipase has been extensively used to study the triacylglycerol fatty acid composition and the in vitro digestion of oils and fats. The ac- tion of this enzyme may be coupled to analytical methods as GC, HPLC, HPSEC, TLC- -FID, etc. as a useful tool for understanding the composition and digestion of thermal oxi- dized oils. Pancreatic lipase hydrolysis occurs in the water/oil interface, and it presents a behaviour that seems to be Michaelian, in which the apparent Km and the apparent Vmax of the enzymatic process depend more on the type of oil tested than on the degree of alter- ation. The kinetic behaviour of pancreatic lipase towards thermally oxidized oils also de- pends on the presence of natural tensioactive compounds present in the oil and surfac- tants formed during the frying.
    [Show full text]
  • Paraoxonase Role in Human Neurodegenerative Diseases
    antioxidants Review Paraoxonase Role in Human Neurodegenerative Diseases Cadiele Oliana Reichert 1, Debora Levy 1 and Sergio P. Bydlowski 1,2,* 1 Lipids, Oxidation, and Cell Biology Group, Laboratory of Immunology (LIM19), Heart Institute (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 05403-900, Brazil; [email protected] (C.O.R.); [email protected] (D.L.) 2 Instituto Nacional de Ciencia e Tecnologia em Medicina Regenerativa (INCT-Regenera), CNPq, Rio de Janeiro 21941-902, Brazil * Correspondence: [email protected] Abstract: The human body has biological redox systems capable of preventing or mitigating the damage caused by increased oxidative stress throughout life. One of them are the paraoxonase (PON) enzymes. The PONs genetic cluster is made up of three members (PON1, PON2, PON3) that share a structural homology, located adjacent to chromosome seven. The most studied enzyme is PON1, which is associated with high density lipoprotein (HDL), having paraoxonase, arylesterase and lactonase activities. Due to these characteristics, the enzyme PON1 has been associated with the development of neurodegenerative diseases. Here we update the knowledge about the association of PON enzymes and their polymorphisms and the development of multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) and Parkinson’s disease (PD). Keywords: paraoxonases; oxidative stress; multiple sclerosis; amyotrophic lateral sclerosis; Alzhei- mer’s disease; Parkinson’s disease 1. Introduction Over the years, biotechnological changes and advances have guaranteed the popula- tion a significant increase in life expectancy that does not necessarily involve an increase in quality of life and/or having a healthy old age.
    [Show full text]
  • Functional Analyses of Human Serum Paraoxonase1 (Hupon1) Mutants Using
    Functional Analyses of Human Serum Paraoxonase1 (HuPON1) Mutants Using Drop Coating Deposition Raman Difference Spectroscopy THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Hua Ying Graduate Program in Chemistry The Ohio State University 2010 Master's Examination Committee: Professor Terry L. Gustafson, Advisor Professor Thomas J. Magliery Copyright by Hua Ying 2010 Abstract We present work on the structural implications of specific mutants of Paraoxonase1 (PON1) G2E6, and the turnover rate upon bonding of the enzymes with paraoxon when compared to the wild-type enzyme by using vibrational spectroscopy. A new Raman spectroscopy called Drop Coating Deposition Raman (DCDR) is utilized in our work. The Raman band changes in the paraoxon/H115W system are in good agreement with computational calculations and are strong evidence of the formation of the paraoxon hydrolysis product, p-nitrophenol in the reaction system. The corresponsive turnover rates of G2E6 wild-type and its two mutants, H115W and H115T, are also observed in DCDR spectra. ii Dedication This document is dedicated to my friends and family. iii Acknowledgments I would like to thank my advisor, Prof. Terry Gustafson for his encouragement, support, guidance, and motivation. I also wish to thank our collaborators Prof. Thomas Magliery, Prof. Christopher Hadad and the members of their groups for assistance on the U54 project. I would like to thank Rachel Baldauff for going through all the U54 program meetings with me. I also want to thank Lynetta Mier for helping me with editing my thesis in every detail.
    [Show full text]
  • Calcineurin/Nfat Signaling Is Required for Perinatal Lung Maturation and Function
    Calcineurin/Nfat signaling is required for perinatal lung maturation and function Vrushank Davé, … , Gerald R. Crabtree, Jeffrey A. Whitsett J Clin Invest. 2006;116(10):2597-2609. https://doi.org/10.1172/JCI27331. Research Article Pulmonology Pulmonary surfactant proteins and lipids are required for lung function after birth. Lung immaturity and resultant surfactant deficiency cause respiratory distress syndrome, a common disorder contributing to morbidity and mortality in preterm infants. Surfactant synthesis increases prior to birth in association with formation of the alveoli that mediate efficient gas exchange. To identify mechanisms controlling perinatal lung maturation, the Calcineurin b1 (Cnb1) gene was deleted in the respiratory epithelium of the fetal mouse. Deletion of Cnb1 caused respiratory failure after birth and inhibited the structural maturation of the peripheral lung. Synthesis of surfactant and a lamellar body–associated protein, ABC transporter A3 (ABCA3), was decreased prior to birth. Nuclear factor of activated T cells (Nfat) calcineurin-dependent 3 (Nfatc3), a transcription factor modulated by calcineurin, was identified as a direct activator of Sftpa, Sftpb, Sftpc, Abca3, Foxa1, and Foxa2 genes. The calcineurin/Nfat pathway controls the morphologic maturation of lungs prior to birth and regulates expression of genes involved in surfactant homeostasis that are critical for adaptation to air breathing. Find the latest version: https://jci.me/27331/pdf Research article Calcineurin/Nfat signaling is required for perinatal lung maturation and function Vrushank Davé,1 Tawanna Childs,1 Yan Xu,1 Machiko Ikegami,1 Valérie Besnard,1 Yutaka Maeda,1 Susan E. Wert,1 Joel R. Neilson,2 Gerald R. Crabtree,2 and Jeffrey A.
    [Show full text]
  • Impact of Intrauterine Fetal Resuscitation with Oxygen on Oxidative Stress in the Developing Rat Brain Jia Jiang1,4, Tusar Giri1, Nandini Raghuraman2, Alison G
    www.nature.com/scientificreports OPEN Impact of intrauterine fetal resuscitation with oxygen on oxidative stress in the developing rat brain Jia Jiang1,4, Tusar Giri1, Nandini Raghuraman2, Alison G. Cahill3 & Arvind Palanisamy1,2* Use of maternal oxygen for intrauterine resuscitation is contentious because of the lack of evidence for its efcacy and the possibility of fetal harm through oxidative stress. Because the developing brain is rich in lipids and low in antioxidants, it remains vulnerable to oxidative stress. Here, we tested this hypothesis in a term pregnant rat model with oxytocin-induced fetal distress followed by treatment with either room air or 100% oxygen for 6 h. Fetal brains from both sexes were subjected to assays for biomarkers of oxidative stress (4-hydroxynonenal, protein carbonyl, or 8-hydroxy- 2ʹ-deoxyguanosine), expression of genes mediating oxidative stress, and mitochondrial oxidative phosphorylation. Contrary to our hypothesis, maternal hyperoxia was not associated with increased biomarkers of oxidative stress in the fetal brain. However, there was signifcant upregulation of the expression of select genes mediating oxidative stress, of which some were male-specifc. These observations, however, were not accompanied by changes in the expression of proteins from the mitochondrial electron transport chain. In summary, maternal hyperoxia in the setting of acute uteroplacental ischemia-hypoxia does not appear to cause oxidative damage to the developing brain. Maternal oxygen administration is one of the most widely practiced interventions for intrauterine resuscitation of a distressed fetus1–5. However, whether such an intervention improves fetal or neonatal outcomes is question- able. Recent meta-analyses suggest that maternal oxygen does not improve either fetal oxygenation or acid–base status3,5.
    [Show full text]
  • Protective Effect of Paraoxonase-2 Against ER Stress-Induced
    Protective effect of paraoxonase-2 against ER stress-induced apoptosis is lost upon disturbance of calcium-homeostasis Sven Horke, Ines Witte, Petra Wilgenbus, Sebastian Altenhöfer, Maximilian Krueger, Huige Li, Ulrich Förstermann To cite this version: Sven Horke, Ines Witte, Petra Wilgenbus, Sebastian Altenhöfer, Maximilian Krueger, et al.. Protec- tive effect of paraoxonase-2 against ER stress-induced apoptosis is lost upon disturbance ofcalcium- homeostasis. Biochemical Journal, Portland Press, 2008, 416 (3), pp.395-405. 10.1042/BJ20080775. hal-00479011 HAL Id: hal-00479011 https://hal.archives-ouvertes.fr/hal-00479011 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 11 Aug 2008 as manuscript BJ20080775 Protective effect of paraoxonase-2 against ER stress- induced apoptosis is lost upon disturbance of calcium- homeostasis Sven Horke*, Ines Witte, Petra Wilgenbus, Sebastian Altenhöfer, Maximilian Krüger, Huige Li, Ulrich Förstermann From the Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany. *Address correspondence to: Sven Horke, Ph.D. Department of Pharmacology Johannes Gutenberg University Obere Zahlbacher Strasse 67 55131 Mainz Germany Email: [email protected] Phone: +49 6131 39 33 192 Fax: +49 6131 39 36 611 Running head: Regulation of PON2 expression during ER stress and Ca2+-disturbance THIS IS NOT THE VERSION OF RECORD - see doi:10.1042/BJ20080775 Accepted Manuscript Licenced copy.
    [Show full text]
  • Are Common Polymorphisms of the Lipoprotein Lipase and Human Paraoxonase-1 Genes Associated with the Metabolic Syndrome in South
    & Experim l e ca n i t in a l l C C f a Journal of Clinical & Experimental o r d Prakaschandra et al., J Clin Exp Cardiolog 2016, l i a o n l o r 7:6 g u y o J Cardiology DOI: 10.4172/2155-9880.1000452 ISSN: 2155-9880 Research Article Open Access Are Common Polymorphisms of the Lipoprotein Lipase and Human Paraoxonase-1 Genes Associated with the Metabolic Syndrome in South African Asian Indians? Rosaley Prakaschandra1, Michelle Gordon2 and Datshana P Naidoo3* 1Department of Biomedical and Clinical Technology, Durban University of Technology, South Africa 2School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, South Africa 3Department of Cardiology, University of KwaZulu-Natal, South Africa *Corresponding author: Datshana P Naidoo, Department of Cardiology, University of KwaZulu-Natal, Tel: 031-2402224/2207; E-mail: [email protected] Received date: May 16, 2016; Accepted date: June 20, 2016; Published date: June 30, 2016 Copyright: © 2016 Prakaschandra R, et al. This is an open -access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract A cross-sectional study was performed to determine the possible contribution of the Human Paraoxonase-1 (PON1) and Lipoprotein Lipase (LPL) polymorphisms to the risk of the metabolic syndrome (MetS) in 817 participants of South African Asian Indian ancestry. Demographic and anthropometric data, including fasting blood for analysis of glycaemic and lipid parameters was collected. DNA was isolated from peripheral blood and allelic polymorphisms at positions Q192R, L55M in the PON1 gene and S447X and N291S in the LPL gene were studied using real-time PCR.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub
    US 2003O19897OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub. Date: Oct. 23, 2003 (54) GENOSTICS clinical trials on groups or cohorts of patients. This group data is used to derive a Standardised method of treatment (75) Inventor: Gareth Wyn Roberts, Cambs (GB) which is Subsequently applied on an individual basis. There is considerable evidence that a significant factor underlying Correspondence Address: the individual variability in response to disease, therapy and FINNEGAN, HENDERSON, FARABOW, prognosis lies in a person's genetic make-up. There have GARRETT & DUNNER been numerous examples relating that polymorphisms LLP within a given gene can alter the functionality of the protein 1300 ISTREET, NW encoded by that gene thus leading to a variable physiological WASHINGTON, DC 20005 (US) response. In order to bring about the integration of genomics into medical practice and enable design and building of a (73) Assignee: GENOSTIC PHARMA LIMITED technology platform which will enable the everyday practice (21) Appl. No.: 10/206,568 of molecular medicine a way must be invented for the DNA Sequence data to be aligned with the identification of genes (22) Filed: Jul. 29, 2002 central to the induction, development, progression and out come of disease or physiological States of interest. Accord Related U.S. Application Data ing to the invention, the number of genes and their configu rations (mutations and polymorphisms) needed to be (63) Continuation of application No. 09/325,123, filed on identified in order to provide critical clinical information Jun. 3, 1999, now abandoned. concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome.
    [Show full text]
  • The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases
    International Journal of Molecular Sciences Review The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases Anna Wysocka 1,2,* and Agnieszka Zwolak 1,3 1 Chair of Internal Medicine and Department of Internal Medicine in Nursing, Faculty of Health Sciences, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 2 Chair and Department of Cardiology, Medical University of Lublin, 20-954 Lublin, Poland 3 Chair and Department of Endocrinology, Medical University of Lublin, 20-954 Lublin, Poland * Correspondence: [email protected]; Tel.: +48-814487720 Abstract: The human paraoxonase (PON) gene cluster is comprised of three contiguous genes (PON1, PON2 and PON3) of presumably common origin coding three lactonases of highly similar struc- ture and substrate specificity. The catalytic activity of PON proteins is directed toward artificial organophosphates and in physiological conditions toward thiolactones and oxidized phospholipids. Consequently, PON enzymes are regarded as an effective defense against oxidative stress and, as a result, against atherosclerosis development. Additionally, both PON’s serum activity and its con- centration are influenced by several polymorphic variations in coding and noncoding DNA regions of the PON gene cluster remaining in linkage disequilibrium. Hence, the genetic polymorphism of the PON gene cluster may contribute to atherosclerotic process progression or deceleration. In this review the authors analyzed the relevance of noncoding DNA polymorphic variations of PON genes in atherosclerosis-related diseases involving coronary and peripheral artery disease, stroke, diabetes mellitus, dementia and renal disease and concluded that the effect of PON gene cluster’ Citation: Wysocka, A.; Zwolak, A. polymorphism has a considerable impact on the course and outcome in these conditions.
    [Show full text]